Clinical trials: Stroke Recurrence
Ischemic Stroke
Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke Patients
This cohort study will evaluate the relatiobship of stroke recurrence and anti-platelet resistance in ischemic stroke patients
- Trial name
- NCT03823274
- Testing
- Aspirin, Clopidogrel
- Where
- South Korea
- Volunteers
- 1,011 people
- Sponsor
- Yuhan Corporation
Acute Ischemic Stroke
An Application Provides Personalized Suggestions Based on Secondary Prevention Risk Factors to Stroke Patients
This study applied an application that provides personalized suggestions and explore the effect of this actual intervention on reducing the risk of stroke recurrence
- Trial name
- NCT07098143
- Testing
- Risk factor management
- Volunteers
- 5,092 people
- Sponsor
- Xuanwu Hospital, Beijing
Atrial Fibrillation, Oral Anticoagulation
Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
Patients with atrial fibrillation (AF) who have had a prior stroke are at very high risk of recurrent ischemic stroke. About 40% of these strokes are due to large emboli which result in large cerebral vessel occlusion (LVO).
- Conditions
- Atrial Fibrillation, Oral Anticoagulation, Stroke, Implant
- Trial name
- INTERCEPT (NCT05723926)
- Testing
- Vine Filter
- Where
- 21 sites in United States, Brazil and 2 more
- Volunteers
- 2,000 people
- Sponsor
- Javelin Medical
Ischemic Stroke, Digital Health
Prevention of Ischemic Stroke Recurrence Using Digital Technology Application
The goal of this study is to find out whether a comprehensive management program that uses a smart bracelet and a mobile app can help people who have had an ischemic stroke (a type of stroke caused by a blocked blood vessel in…
- Trial name
- DESIRE (NCT07825311)
- Testing
- Digital Prevention Management, Usual Stroke Secondary Prevention Management
- Where
- China
- Volunteers
- 1,696 people
- Sponsor
- Affiliated Hospital of Nantong University
Ischemic Stroke
hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP)
Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase can play a role in preventing recurrent vascular events from ischemic heart disease patients, whose mechanism consists in not only the reduction of serum…
- Trial name
- NCT00361699
- Testing
- Statin
- Where
- 2 sites in Japan
- Volunteers
- 1,095 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Stroke, Atrial Fibrillation
Atrial Fibrillation and Premature Atrial Complexes in Patients With Ischemic Stroke.
The purpose of this study is to improve secondary prevention of ischemic stroke patients by 1. Estimating prevalence and the prognostic significance of frequent premature atrial complexes in ischemic stroke patients in relation…
- Conditions
- Stroke, Atrial Fibrillation, Premature Atrial Complexes
- Trial name
- Pacific (NCT02180542)
- Where
- Denmark
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Acute Ischemic Stroke
Efficacy and Safety of Indobufen, Aspirin, Cilostazol and Clopidogrel in the Treatment of Ischemic Stroke
Through a single-center retrospective cohort study of acute ischemic stroke (AIS) patients receiving secondary prevention with indobufen, clopidogrel, cilostazol, or aspirin as monotherapy or dual therapy, we aim to compare the…
- Trial name
- NCT07604298
- Testing
- indubufen, aspirin, clopidogrel, cilostazol
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Transient Ischemic Attack, Stroke
Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)
Current management of patients with TIA (transient ischemic attack) or minor stroke includes the prompt investigation and treatment in the days and weeks after the event.
- Trial name
- NCT00109382
- Testing
- Aspirin, Clopidogrel, Simvastatin
- Where
- 18 sites in United States, Canada
- Volunteers
- 500 people
- Sponsor
- University of Calgary
Stroke
Stroke Homecare and Recurrence Prevention
Background and Significance: Stroke is the leading cause of death in China, placing a heavy burden on patients, families, and society.
- Trial name
- SHARP (NCT06810024)
- Testing
- Home-based therapy, Standard Care (in control arm)
- Volunteers
- 1,614 people
- Sponsor
- Peking Union Medical College
Ischemic Stroke, Acute, TIA
Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）
This is a multicenter, double-blind, double-dummy, randomized clinical trial comparing the efficacy and safety of tirofiban versus placebo in preventing recurrence of stroke for patients with intracranial artery stenosis and…
- Conditions
- Ischemic Stroke, Acute, TIA, Symptomatic Intracranial Artery Stenosis
- Trial name
- NCT06319846
- Testing
- Tirofiban
- Where
- 5 sites in China
- Volunteers
- 4,674 people
- Sponsor
- Beijing Tiantan Hospital
Intracranial Atherosclerosis
Remote Ischemic Conditioning for Avoiding Recurrence of Symptomatic Intracranial Atherosclerotic Stenosis (sICAS)
The primary objective of the study will be to determine whether remote limb ischemic conditioning (RLIC) compared with sham RLIC (placebo) treatment reduces the 12-month risk of recurrent IS in patients with a recent TIA or IS…
- Trial name
- NCT02534545
- Testing
- Doctormate® (200mmHg), Doctormate® (60mmHg)
- Where
- 50 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Ji Xunming,MD,PhD
Atherosclerosis
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated…
- Trial name
- CANTOS (NCT01327846)
- Testing
- Canakinumab, Standard of care
- Where
- 1,131 sites in United States, Argentina and 38 more
- Volunteers
- 10,066 people
- Sponsor
- Novartis Pharmaceuticals
Stroke, Transient Ischemic Attack
Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events
The purpose of this study is to assess the effects of a 3-month regimen of clopidogrel initiated with a loading dose (LD) of 300 mg followed by 75 mg/day during the first 21days versus a 3-month regimen of ASA 75 mg/day alone on…
- Trial name
- CHANCE (NCT00979589)
- Testing
- Clopidogrel
- Where
- China
- Volunteers
- 5,100 people
- Sponsor
- Beijing Tiantan Hospital
Ischemic Stroke, Antiplatelet Effect
Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke
This clinical trail will evaluate the effect of Sanchitongshu combined with antiplatelet drugs (Aspirin or Clopidogrel) in the treatment of high-risk ischemic stroke patients in adults.
- Trial name
- NCT04142151
- Testing
- Sanchitongshu, Aspirin, Clopidogrel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Stroke, Ischemic
BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis
This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic…
- Conditions
- Stroke, Ischemic, Atrial Fibrillation, Intracrnaial Arterioscelrosis
- Trial name
- NCT07237308
- Testing
- Apixaban, Clopidogrel
- Where
- South Korea
- Volunteers
- 586 people
- Sponsor
- Yonsei University
Acute Ischemic Stroke
An Application Provides Temperature-related Health Risk Warnings and Protective Recommendations on Stroke
This study applied an application to provide early warnings and advice for stroke patients and explored the impact of this intervention on reducing the risk of stroke recurrence
- Trial name
- NCT07097428
- Testing
- Temperature health risk early warning
- Volunteers
- 5,092 people
- Sponsor
- Xuanwu Hospital, Beijing
Intracerebral Haemorrhage
Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage
BEAT ICH will be a pragmatic, randomised, placebo-controlled, blinded, superiority clinical trial aiming to recruit 5676 patients aged ≥18 years who survive ICH and assign them 1:1 to starting antiplatelet monotherapy (Aspirin 75…
- Trial name
- BEAT-ICH (NCT07243704)
- Testing
- Aspirin 75 mg daily
- Where
- 33 sites in India
- Volunteers
- 5,676 people
- Sponsor
- Christian Medical College and Hospital, Ludhiana, India
Cervical Artery Dissection, Pregnancy Complications
Risk of Recurrent CeAD After Pregnancy
Primary objective: To determine whether pregnancy increases the risk of recurrent CeAD and delayed stroke in women with prior CeAD based on long-term data.
- Trial name
- LONG-RECAP (NCT06258109)
- Where
- 12 sites in United States, Argentina and 7 more
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Basel, Switzerland
Stroke, Transient Ischemic Attack
Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II
The primary objective of this trial is to assess the effects of ticagrelor plus aspirin versus clopidogrel plus aspirin on reducing the 3-month risk of any stroke (both ischemic and hemorrhagic, primary outcome) when initiated…
- Trial name
- CHANCE-2 (NCT04078737)
- Testing
- Ticagrelor and Aspirin, Clopidogrel and Aspirin
- Where
- 214 sites in China
- Volunteers
- 6,412 people
- Sponsor
- Beijing Tiantan Hospital
Stroke, Cardiovascular Diseases
MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway
Annually 13000 Norwegians experience an ischemic stroke. The number of stroke is anticipated to increase with 50% within 2030 due to a growing number of elderly.
- Conditions
- Stroke, Cardiovascular Diseases, Cardiovascular Risk Factor, Brain Ischemia
- Trial name
- NCT03962127
- Testing
- no intervention
- Where
- 8 sites in Norway
- Volunteers
- 800 people
- Sponsor
- Norwegian University of Science and Technology